Qelbree

Active Ingredient(s): Viloxazine Hydrochloride
FDA Approved: * April 2, 2021
Pharm Company: * SUPERNUS PHARMS
Category: ADD / ADHD

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Qelbree Overview

Viloxazine, sold under the brand name Qelbree among others, is a medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and depression.[1][5] It was marketed for more than two decades as an antidepressant in Europe before being repurposed as a treatment for ADHD and launched in the United States in April 2021.[5][1][6][7] Viloxazine is taken by mout...

Read more Qelbree Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Viloxazine

Recent Qelbree Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Viloxazine Hydrochloride
  • Capsule, Extended Release: 100mg, 150mg, 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Qelbree: (3 results)

Sorted by National Drug Code
  • 17772-131 Qelbree 100 mg Oral Capsule, Extended Release by Supernus Pharmaceuticals, Inc
  • 17772-132 Qelbree 150 mg Oral Capsule, Extended Release by Supernus Pharmaceuticals, Inc
  • 17772-133 Qelbree 200 mg Oral Capsule, Extended Release by Supernus Pharmaceuticals, Inc

Other drugs which contain Viloxazine Hydrochloride or a similar ingredient: (1 result)